JOHNSON KRISTINA M 4
4 · Churchill Capital Corp X/Cayman · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
Infleqtion (INFQ) Director Kristina M. Johnson Receives Award
What Happened
- Kristina M. Johnson, a director of Infleqtion, Inc. (ticker INFQ, formerly Churchill Capital Corp X), was credited with two awards on Feb 13, 2026: 33,120 shares of common stock and 373,458 shares described as derivative securities. No cash price was reported for these items; they were issued in connection with the merger/recapitalization that closed as described in the filing.
- The 373,458 derivative shares represent common stock issued upon conversion of the company’s Series C-1 preferred stock pursuant to the merger. The 33,120 shares and the converted/derivative shares were received rather than bought or sold.
Key Details
- Transaction date: 2026-02-13; Filing date (Form 4): 2026-02-18 (filed five days after the reported transaction).
- Transaction codes: A (Award/Grant/Other Acquisition); price per share: N/A.
- Shares owned after the transaction: Not specified in the filing.
- Notable footnotes from the filing:
- F1: Shares issued pursuant to the Agreement and Plan of Merger and Reorganization dated Sept 8, 2025 (company renamed Infleqtion).
- F2: Derivative shares issued upon conversion of Series C-1 preferred stock.
- F3: Some holdings are held directly by Catalyzer Ventures, LP Fund I; Dr. Johnson may be deemed to beneficially own those via voting/investment power.
- F4: A vesting schedule applies to certain awards (monthly vesting of 1/36 beginning June 1, 2024).
- F5: Legacy stock options were converted into Issuer options with the same terms due to the merger.
- Timing note: Form 4s are generally required within two business days of a transaction; this filing was submitted five days after the transaction date.
Context
- These entries reflect merger-related conversions and awards, not open-market purchases or insider sales. Such merger-driven issuances are typically administrative and do not by themselves indicate deliberate buy/sell market timing by the insider.
- The derivative entry reflects conversion of preferred shares into common stock; some shares remain subject to vesting and some are held via an entity (Catalyzer) over which Dr. Johnson has influence, which may affect beneficial ownership reporting.
Insider Transaction Report
Form 4
JOHNSON KRISTINA M
Director
Transactions
- Award
Common Stock
[F1][F2][F3]2026-02-13+33,120→ 33,120 total(indirect: See footnote) - Award
Stock Option (Right to Buy)
[F1][F5][F4]2026-02-13+373,458→ 373,458 totalExercise: $0.90Exp: 2034-06-05→ Common Stock (373,458 underlying)
Footnotes (5)
- [F1]Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of September 8, 2025, by and among Churchill Capital Corp X, a Delaware corporation now known as Infleqtion, Inc. ("Acquiror"), AH Merger Sub I, Inc., a direct, wholly-owned Subsidiary of Acquiror ("Merger Sub I"), AH Merger Sub II, LLC, a direct, wholly-owned Subsidiary of Acquiror ("Merger Sub II" and together with Merger Sub I, "Merger Subs") and ColdQuanta, Inc. (the "Company") pursuant to which (a) Merger Sub I was merged with and into the Company, and the Company continued as the surviving corporation and immediately thereafter, (b) the Company merged with and into Merger Sub II, and Merger Sub II became the surviving company and continued in existence as a wholly-owned subsidiary of Acquiror (collectively, the "Mergers"). In connection with the Mergers, Acquiror changed its name to Infleqtion, Inc. (the "Issuer").
- [F2]Represents shares of common stock of the Issuer issued upon conversion of the Company's Series C-1 preferred stock pursuant to the Mergers.
- [F3]Held directly by Catalyzer Ventures, LP Fund I ("Catalyzer"). Dr. Johnson may be deemed to beneficially own shares held by Catalyzer by virtue of her voting power and investment power over such shares.
- [F4]The shares vest on a monthly basis beginning on June 1, 2024 with respect to 1/36 of the total number of shares until such time as the option is 100% vested, subject to the continuous service of the Reporting Person as of each such date.
- [F5]Pursuant to the Mergers, the legacy stock options of the Company were automatically converted into the right to receive stock options of the Issuer with the same terms and conditions.
Signature
/s/ Jason D. Hall, Attorney-in-Fact|2026-02-18